Cargando…

Wide variation in susceptibility of transmitted/founder HIV-1 subtype C Isolates to protease inhibitors and association with in vitro replication efficiency

The gag gene is highly polymorphic across HIV-1 subtypes and contributes to susceptibility to protease inhibitors (PI), a critical class of antiretrovirals that will be used in up to 2 million individuals as second-line therapy in sub Saharan Africa by 2020. Given subtype C represents around half of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sutherland, Katherine A., Collier, Dami A., Claiborne, Daniel T., Prince, Jessica L., Deymier, Martin J., Goldstein, Richard A., Hunter, Eric, Gupta, Ravindra K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5128871/ https://www.ncbi.nlm.nih.gov/pubmed/27901085 http://dx.doi.org/10.1038/srep38153

Ejemplares similares

Generation and characterization of infectious molecular clones of transmitted/founder HIV-1 subtype C viruses
por: Luthuli, Bonisile, et al.
Publicado: (2023)

High throughput generation and characterization of replication-competent clade C transmitter-founder simian human immunodeficiency viruses
por: Dutta, Debashis, et al.
Publicado: (2018)

HIV-1 subtype C transmitted founders modulate dendritic cell inflammatory responses
por: Lumngwena, Evelyn Ngwa, et al.
Publicado: (2020)

Impact of transmitted CTL escape mutations on replicative capacity and HIV pathogenesis in early infection
por: Prince, J, et al.
Publicado: (2012)

Rational design and in vivo selection of SHIVs encoding transmitted/founder subtype C HIV-1 envelopes
por: O’Brien, Sean P., et al.
Publicado: (2019)

In vitro replicative fitness of early Transmitted founder HIV-1 variants and sensitivity to Interferon alpha
por: Ashok kumar, Manickam, et al.
Publicado: (2020)

Adaptation of a transmitted/founder simian-human immunodeficiency virus for enhanced replication in rhesus macaques
por: Bauer, Anya, et al.
Publicado: (2023)

Transmitted/founder SHIV.D replicates in the brain, causes neuropathogenesis, and persists on combination antiretroviral therapy in rhesus macaques
por: Podgorski, Rachel M., et al.
Publicado: (2023)

Publisher Correction: In vitro replicative fitness of early Transmitted founder HIV-1 variants and sensitivity to Interferon alpha
por: Ashokkumar, Manickam, et al.
Publicado: (2020)

Transmission of Multiple HIV-1 Subtype C Transmitted/founder Viruses into the Same Recipients Was not Determined by Modest Phenotypic Differences
por: Song, Hongshuo, et al.
Publicado: (2016)

Role of Transmitted Gag CTL Polymorphisms in Defining Replicative Capacity and Early HIV-1 Pathogenesis
por: Prince, Jessica L., et al.
Publicado: (2012)

HIV-1 subtype influences susceptibility and response to monotherapy with the protease inhibitor lopinavir/ritonavir
por: Sutherland, K. A., et al.
Publicado: (2015)

Heterosexual Transmission of Subtype C HIV-1 Selects Consensus-Like Variants without Increased Replicative Capacity or Interferon-α Resistance
por: Deymier, Martin J., et al.
Publicado: (2015)

Resistance of Transmitted Founder HIV-1 to IFITM-Mediated Restriction
por: Foster, Toshana L., et al.
Publicado: (2016)

Characterization of Near Full-Length Transmitted/Founder HIV-1 Subtype D and A/D Recombinant Genomes in a Heterosexual Ugandan Population (2006–2011)
por: Balinda, Sheila N., et al.
Publicado: (2022)

Evidence for Reduced Drug Susceptibility without Emergence of Major Protease Mutations following Protease Inhibitor Monotherapy Failure in the SARA Trial
por: Sutherland, Katherine A., et al.
Publicado: (2015)

Correction: Evidence for Reduced Drug Susceptibility without Emergence of Major Protease Mutations following Protease Inhibitor Monotherapy Failure in the SARA Trial
por: Sutherland, Katherine A., et al.
Publicado: (2016)

Dynamics and frequency of Gag transmitted polymorphisms in Zambia
por: Schaefer, M, et al.
Publicado: (2012)

Transmitted/Founder Simian Immunodeficiency Virus Envelope Sequences in Vesicular Stomatitis and Semliki Forest Virus Vector Immunized Rhesus Macaques
por: Gambhira, Ratish, et al.
Publicado: (2014)

Sexually transmitted founder HIV-1 viruses are relatively resistant to Langerhans cell-mediated restriction
por: Hertoghs, Nina, et al.
Publicado: (2019)

A sequestered fusion peptide in the structure of an HIV-1 transmitted founder envelope trimer
por: Ananthaswamy, Neeti, et al.
Publicado: (2019)

Negative and Positive Selection Pressure During Sexual Transmission of Transmitted Founder HIV-1
por: Nijmeijer, Bernadien M., et al.
Publicado: (2019)

Identification of early-induced broadly neutralizing activities against transmitted founder HIV strains
por: Lucas, Julie, et al.
Publicado: (2023)

Sexually-Transmitted/Founder HIV-1 Cannot Be Directly Predicted from Plasma or PBMC-Derived Viral Quasispecies in the Transmitting Partner
por: Frange, Pierre, et al.
Publicado: (2013)

Genetic variation of the HIV-1 subtype C transmitted/founder viruses long terminal repeat elements and the impact on transcription activation potential and clinical disease outcomes
por: Madlala, Paradise, et al.
Publicado: (2023)

Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection
por: Salazar-Gonzalez, Jesus F., et al.
Publicado: (2009)

Polygenic risk scores of several subtypes of epilepsies in a founder population
por: Moreau, Claudia, et al.
Publicado: (2020)

Conformational flexibility of HIV-1 envelope glycoproteins modulates transmitted / founder sensitivity to broadly neutralizing antibodies
por: Ratnapriya, Sneha, et al.
Publicado: (2023)

A deeper view of transmitted/founder viruses using 454 whole genome deep sequencing
por: Tully, DC, et al.
Publicado: (2012)

Impact of immune escape mutations on HIV-1 fitness in the context of the cognate transmitted/founder genome
por: Song, Hongshuo, et al.
Publicado: (2012)

Use of Dried Blood Spots to Elucidate Full-Length Transmitted/Founder HIV-1 Genomes
por: Salazar-Gonzalez, Jesus F., et al.
Publicado: (2016)

Point of care SARS-CoV-2 nucleic acid testing in schools improves school attendance
por: Collier, Dami A., et al.
Publicado: (2022)

Virological Outcomes of Second-line Protease Inhibitor–Based Treatment for Human Immunodeficiency Virus Type 1 in a High-Prevalence Rural South African Setting: A Competing-Risks Prospective Cohort Analysis
por: Collier, Dami, et al.
Publicado: (2017)

Transmitted/Founder and Chronic Subtype C HIV-1 Use CD4 and CCR5 Receptors with Equal Efficiency and Are Not Inhibited by Blocking the Integrin α4β7
por: Parrish, Nicholas F., et al.
Publicado: (2012)

Foundered
por: Hayes, P. H.
Publicado: (1876)

The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection
por: Goonetilleke, Nilu, et al.
Publicado: (2009)

Maternal Broadly Neutralizing Antibodies Can Select for Neutralization-Resistant, Infant-Transmitted/Founder HIV Variants
por: Martinez, David R., et al.
Publicado: (2020)

Deep Sequencing Reveals Central Nervous System Compartmentalization in Multiple Transmitted/Founder Virus Acute HIV-1 Infection
por: Tovanabutra, Sodsai, et al.
Publicado: (2019)

Identification, Molecular Cloning, and Analysis of Full-Length Hepatitis C Virus Transmitted/Founder Genotypes 1, 3, and 4
por: Stoddard, Mark B., et al.
Publicado: (2015)

HIV-1 Subtype and Reverse Transcriptase Genotype: Role for Geographical Location and Founder Effects
por: Ojesina, Akinyemi I, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_o8voogt58cfh2k4frcp7lcs9nf